Analyst Reco. Incyte Corporation

Equities

INCY

US45337C1027

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 12/05/2026 am IST			5-day change	1st Jan Change
100.32 ^USD	+1.79%		+3.27%	+1.57%

07/05	Incyte Announces 24-Week Data For Opzelura Cream In Adults With Moderate Atopic Dermatitis	CI
02/05	Incyte Announces Fda Approval of Jakafi Xr Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease	CI

Analyst Reco.

29/04	Leerink Partners Adjusts Incyte Price Target to $131 From $129, Maintains Outperform Rating	MT
29/04	Morgan Stanley Adjusts Incyte Price Target to $103 From $102, Maintains Equal Weight Rating	MT
29/04	TD Cowen Adjusts Incyte Price Target to $124 From $123, Maintains Buy Rating	MT
29/04	Stifel Nicolaus Adjusts Incyte Price Target to $123 From $120, Maintains Buy Rating	MT
29/04	Oppenheimer Adjusts Price Target on Incyte to $90 From $84, Maintains Perform Rating	MT
29/04	TD Cowen Raises Incyte Price Target to $124 From $123	MT
28/04	Morgan Stanley Adjusts Price Target on Incyte to $102 From $94, Maintains Equalweight Rating	MT
24/04	Damora Faces Upside As Fast-Follower CALR 'Should Make Bigger Splash,' RBC Says	MT
17/04	Goldman Sachs Adjusts Incyte Price Target to $100 From $98, Maintains Neutral Rating	MT
07/04	RBC Adjusts Price Target on Incyte to $95 From $92, Maintains Sector Perform Rating	MT
24/03	UBS Lowers Price Target on Incyte to $94 From $104	MT
05/03	Evercore ISI Adjusts Price Target on Incyte to $110 From $73, Maintains In Line Rating	MT
26/02	Argus Adjusts Price Target on Incyte to $115 From $100, Maintains Buy Rating	MT
18/02	Barclays Adjusts Price Target on Incyte to $117 From $116, Maintains Overweight Rating	MT
11/02	Deutsche Bank Adjusts Incyte Price Target to $98 From $70, Maintains Hold Rating	MT
11/02	Stifel Adjusts Price Target on Incyte to $120 From $119, Maintains Buy Rating	MT
11/02	TD Cowen Adjusts Price Target on Incyte to $123 From $128, Maintains Buy Rating	MT
11/02	Goldman Sachs Adjusts Price Target on Incyte to $98 From $90, Maintains Neutral Rating	MT
11/02	Morgan Stanley Raises Price Target on Incyte to $102 From $94, Keeps Equalweight Rating	MT
11/02	RBC Cuts Price Target on Incyte to $92 From $95, Keeps Sector Perform Rating	MT
10/02	Wells Fargo Adjusts Incyte Price Target to $101 From $107, Maintains Equal Weight Rating	MT
06/02	Piper Sandler Adjusts Price Target on Incyte to $110 From $102, Maintains Overweight Rating	MT
05/02	Barclays Adjusts Price Target on Incyte to $116 From $115, Maintains Overweight Rating	MT
05/02	HC Wainwright Initiates Incyte at Buy With $135 Price Target	MT
20/01	RBC Raises Price Target on Incyte to $95 From $92, Keeps Sector Perform Rating	MT